HIV/AIDS NDAs For Fixed-Dose Combination Will Be Exempt From User Fees
This article was originally published in The Pink Sheet Daily
Executive Summary
Expedited FDA review process for combination antiretroviral drugs announced at World Health Organization meeting. Generic versions of patented medicines would receive a “tentative” approval and be eligible for use in the Administration’s $15 bil. assistance program.